Alnylam Pharmaceuticals (NASDAQ:ALNY) Receives Buy Rating from HC Wainwright

Key Points

• Alnylam Pharmaceuticals received a reiterated "buy" rating from HC Wainwright, with a price target of $570.00, indicating a potential upside of 24.74% from its current price.
• Several analysts have upgraded their price objectives for Alnylam, with an average target of $448.04, highlighting strong institutional interest as they own 92.97% of the company's stock.
• The company reported a $0.32 EPS for the last quarter, surpassing estimates, and experienced a 17.3% year-over-year increase in revenue, amounting to $773.69 million.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report)'s stock had its "buy" rating reiterated by analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They presently have a $570.00 price target on the biopharmaceutical company's stock. HC Wainwright's price target suggests a potential upside of 24.74% from the company's current price.

ALNY has been the topic of several other reports. Stifel Nicolaus lifted their price objective on Alnylam Pharmaceuticals from $441.00 to $495.00 and gave the stock a "buy" rating in a report on Monday. Piper Sandler lifted their price objective on Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the stock an "overweight" rating in a report on Friday, August 1st. Wall Street Zen upgraded Alnylam Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, October 4th. JPMorgan Chase & Co. lifted their price objective on Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the stock an "overweight" rating in a report on Wednesday, August 6th. Finally, Citigroup lifted their price objective on Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the stock a "buy" rating in a report on Tuesday, September 2nd. Twenty-four analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $448.04.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ:ALNY opened at $456.95 on Friday. The company has a market cap of $59.90 billion, a P/E ratio of -185.00 and a beta of 0.36. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. Alnylam Pharmaceuticals has a one year low of $205.87 and a one year high of $484.21. The business's 50-day simple moving average is $450.21 and its 200 day simple moving average is $343.85.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating the consensus estimate of ($0.54) by $0.86. The business had revenue of $773.69 million for the quarter, compared to the consensus estimate of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The company's revenue was up 17.3% on a year-over-year basis. During the same period last year, the business posted ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, sell-side analysts forecast that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director Dennis A. Ausiello sold 31,448 shares of the business's stock in a transaction on Thursday, August 14th. The stock was sold at an average price of $436.58, for a total transaction of $13,729,567.84. Following the completion of the transaction, the director owned 911 shares in the company, valued at approximately $397,724.38. The trade was a 97.18% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Jeffrey V. Poulton sold 3,821 shares of the business's stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total value of $1,727,283.05. Following the transaction, the executive vice president owned 54,052 shares of the company's stock, valued at $24,434,206.60. This trade represents a 6.60% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 98,144 shares of company stock worth $44,160,261. 1.50% of the stock is owned by company insiders.

Institutional Trading of Alnylam Pharmaceuticals

Several institutional investors have recently modified their holdings of ALNY. Norges Bank acquired a new stake in shares of Alnylam Pharmaceuticals in the second quarter valued at $662,837,000. Holocene Advisors LP acquired a new position in Alnylam Pharmaceuticals during the second quarter valued at $194,616,000. Orbis Allan Gray Ltd raised its position in Alnylam Pharmaceuticals by 29.8% during the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company's stock valued at $691,771,000 after buying an additional 486,489 shares during the period. Vanguard Group Inc. increased its position in Alnylam Pharmaceuticals by 2.5% in the 1st quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company's stock worth $3,525,544,000 after purchasing an additional 323,206 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 1st quarter valued at approximately $69,292,000. Institutional investors and hedge funds own 92.97% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.